Insider Monkey (blog) | What Does Celgene Corporation (CELG)'s Failed Trial Mean for Investors? Insider Monkey (blog) Biogen Idec Inc (NASDAQ:BIIB) and Roche offer rituximab as a first-line combination treatment, while Sanofi offers alemtuzumab as a second line treatment. Rituximab brought in $7.2 billion in sales in 2012 -- making it one of the most successful drugs ... |
